Western blot (WB) experiments revealed that the expression level of CYP7A1 starts increasing at the stage of NASH, continues to rise until the onset of tumours, and subsequently declines during the tumour stage. This evidence concerns the gene CYP7A1 and metabolic dysfunction-associated steatohepatitis.